0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Gastroenterology and Hepatology

Gary Gitnick, MD
JAMA. 1987;258(16):2243-2245. doi:10.1001/jama.1987.03400160097021.
Text Size: A A A
Published online

Dramatic advances have occurred in many areas of gastroenterology. For example, new drugs are being developed for the treatment of Crohn's disease and ulcerative colitis. One of the most important is salicylazosulfapyridine, which has been used for years to treat acute attacks of ulcerative colitis and to minimize the risk of relapse. The drug reaches the colon intact and there it is split into 5-aminosalicylic acid and sulfapyridine. Aminosalicylic acid is the active moiety, with sulfapyridine acting as a carrier but also being responsible for many side effects such as nausea and vomiting. New oral and rectal formulations of 5-aminosalicylic are under investigation. The oral preparations can be divided into two groups: diazoderivatives, in which 5-aminosalicylic is linked through a diazobond to a similar molecule, and preparations of 5-aminosalicylic encapsulated in a slow-release or time-release capsule and liberated by physical or chemical mechanisms. Both formulations have been found to be

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();